Skip to content

Effect of omega-3 fatty acids supplementation on serum levels of malondialdehyde, total antioxidant capacity and paraoxonase1 in polycystic ovary syndrome patients

Effect of omega-3 fatty acids supplementation on serum levels of malondialdehyde, total antioxidant capacity and paraoxonase1 in polycystic ovary syndrome patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201106243664N5
Enrollment
60
Registered
2011-07-18
Start date
2010-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 2 capsules of omega-3 containing 360 mg EPA and 240 mg DHA for 2 months. Intervention 2: Control group: 2 placebo capsules containing sunflower oil for 2 months.
Placebo
Control group: 2 placebo capsules containing sunflower oil for 2 months

Sponsors

Nutritional Research Center,Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:woman with polycystic ovary syndrome; 20-35 years old and BMI=25-40; Exclusion criteria: Thyroid disorders; hyperprolactinemia; cushing syndrome; liver,kidney and cardiovascular disease; diabetes; pregnancy and lactation; smoking; use of anti obesity drugs; lipid lowering agent; glucocorticids; anti coagulation drugs; use a lowering weight diet; have a usual sports program; receiving omega-3 supplement during 2 month ago and receiving any nutritional supplements during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Total antioxidant capacity. Timepoint: baseline and at the end of intervention. Method of measurement: FRAP.;Paraxonase1(PON1). Timepoint: baseline and at the end of intervention. Method of measurement: Spectrophotometry.

Primary

MeasureTime frame
Malondialdehyde(MDA). Timepoint: baseline and at the end of intervention. Method of measurement: Fluorimetry method.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElahe Mohammadi

Tabriz University of Medical science

e.mohamadi52@yahoo.com+98 41 1335 7580

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026